臨床検査55巻2号

2011年02月発行

今月の主題 腸内細菌叢 各論 〈腸内細菌叢と疾患〉

過敏性腸症候群

著者： 福土審¹

所属機関： ¹東北大学大学院医学系研究科行動医学

ページ範囲：P.155 - P.160

過敏性腸症候群(IBS)とは，腹痛・腹部不快感と便通異常が持続する機能性消化管障害である．IBSの病因と病態生理の両面において腸内細菌叢の役割が重視されつつある．腸内細菌叢が撹乱される感染性腸炎に罹患した後にIBSが発症する感染性腸炎後IBSが注目されている．IBS全体としても，腸内細菌叢の異常が検討され，その代謝産物が症状の重症度を左右する結果が報告されている．慎重に計画された介入研究においても，腸内細菌叢の役割が証明されつつある．

参考文献

1) Drossman DA, Corazziari E, Delvaux M, et al:Rome III:The Functional Gastrointestinal Disorders:Third Edition. Degnon Associates, McLean，2006

2) Longstreth GF, Thompson WG, Chey WD, et al:Functional bowel disorders. Gastroenterology　130：1480-1491，2006

3) Chang L, Toner BB, Fukudo S, et al:Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology　130：1435-1446，2006

4) Chaudary NA, Truelove SC:The irritable colon syndrome:A study of clinical features, predisposing causes, and prognosis in 130 cases. Quart J Med　31：307-323，1962

5) Read NW ed:Irritable Bowel Syndrome:New ideas and insights into pathophysiology. Blackwell Scientific Publications, Oxford，pp3-15，1991

6) Gwee KA, Graham JC, McKendrick MW, et al:Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet　347：150-153，1996

7) Mearin F, Perez-Oliveras M, Perello A, et al:Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak:one-year follow-up cohort study. Gastroenterology　129：98-104，2005

8) Spiller R, Garsed K:Postinfectious irritable bowel syndrome. Gastroenterology　136：1979-1988，2009

9) Balsari A, Ceccarelli A, Dubini F, et al:The fecal microbial population in the irritable bowel syndrome. Microbiologica　5：185-194，1982

10) King TS, Elia M, Hunter JO:Abnormal colonic fermentation in irritable bowel syndrome. Lancet　352：1187-1189，1998

11) Si JM, Yu YC, Fan YJ, et al:Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol　10：1802-1805，2004

12) Matto J, Maunuksela L, Kajander K, et al:Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol　43：213-222，2005

13) Malinen E, Rinttila T, Kajander K, et al:Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with realtime PCR. Am J Gastroenterol　100：373-382，2005

14) Maukonen J, Satokari R, Matto J, et al:Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol　55：625-633，2006

15) Wensinck F:Proceedings:the faecal flora of patients with Crohn's disease. Antonie van Leeuwenhoek　41：214-215，1975

16) Seksik P, Rigottier-Gois L, Gramet G, et al:Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut　52：237-242，2003

17) Ott SJ, Musfeldt M, Wenderoth DF, et al:Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut　53：685-693，2004

18) Kirjavainen PV, Apostolou E, Arvola T, et al:Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol Med Microbiol　32：1-7，2001

19) Watanabe S, Narisawa Y, Arase S, et al:Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol　111：587-591，2003

20) Verdu EF, Bercik P, Verma-Gandhu M, et al:Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut　55：182-190，2006

21) Suau A, Bonnet R, Sutren M, et al:Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol　65：4799-4807，1999

22) Reysenbach AL, Giver LJ, Wickham GS, et al:Differential amplification of rRNA genes by polymerase chain reaction. Appl Environ Microbiol　58：3417-3418，1992

23) Kassinen A, Krogius-Kurikka L, Makivuokko H, et al:The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology　133：24-33，2007

24) Moore WE, Moore LH:Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol　61：3202-3207，1995

25) Villani AC, Lemire M, Thabane M, et al:Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology　138：1502-1513，2010

26) Tana C, Umesaki Y, Imaoka A, et al:Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil　22：512-519，2010

27) O'Mahony L, McCarthy J, Kelly P, et al:Lactobacillus and bifidobacterium in irritable bowel syndrome:symptom responses and relationship to cytokine profiles. Gastroenterology　128：541-551，2005

28) Pimentel M, Park S, Mirocha J, et al:The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome:a randomized trial. Ann Intern Med　145：557-563，2006

29) Rousseaux C, Thuru X, Gelot A, et al:Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med　13：35-37，2007

30) Rhee SH, Pothoulakis C, Mayer EA:Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol　6：306-314，2009